Sudeep Pharma IPO: Key Details and Investment Opportunity
The much-anticipated initial public offering (IPO) of Sudeep Pharma has officially announced its price band, marking a significant milestone for the specialty chemicals manufacturer. The company has fixed the price band at ₹563 to ₹593 per equity share, with each share having a face value of Re 1.
IPO Schedule and Important Dates
The subscription window for Sudeep Pharma IPO is scheduled to open on Friday, November 21, and will remain available for investors until Tuesday, November 25. Prior to the public opening, the allocation to anchor investors is set for Thursday, November 20, providing institutional players early access to the offering.
For retail investors, the lot size has been established at 25 equity shares and subsequent multiples of 25 shares. This structure makes the IPO accessible to smaller investors while maintaining orderly trading patterns.
Allocation Strategy and Reservation Quotas
Sudeep Pharma has implemented a carefully planned allocation strategy for its public issue. The company has reserved not more than 50% of shares for qualified institutional buyers (QIBs), ensuring significant institutional participation. For non-institutional investors (NIIs), not less than 15% has been allocated, while retail investors have been guaranteed not less than 35% of the total offering.
The timeline for post-IPO processes is clearly defined. The basis of allotment is tentatively scheduled for finalization on Wednesday, November 26. Investors can expect refunds to be initiated on Thursday, November 27, with successful allottees receiving shares in their demat accounts on the same day. The official listing of Sudeep Pharma shares on both BSE and NSE is projected for Friday, November 28.
Financial Structure and Fund Utilization
The IPO comprises two distinct components. The fresh issue aims to raise ₹95 crore through new shares, while promoters will offer 1.34 crore equity shares via an offer-for-sale (OFS). Notably, the company increased the OFS portion from the initially planned 1 crore shares mentioned in the DRHP submitted to SEBI in June.
Backed by Nuvama, Sudeep Pharma has outlined clear plans for utilizing the fresh issue proceeds. The company intends to allocate ₹78.8 crore specifically for purchasing machinery to enhance its production line at the Nandesari facility I. The remaining funds will be directed toward general corporate purposes, supporting overall business growth and operational requirements.
Company Background and Market Position
Based in Gujarat, Sudeep Pharma has established itself as a leading manufacturer of food-grade iron phosphate, particularly for infant nutrition, clinical nutrition, and the food and beverage industries. The company operates six production facilities with a combined capacity of 50,000 MT, specializing in essential minerals including calcium, iron, magnesium, zinc, potassium, and sodium.
The company's product portfolio is extensive, offering over 200 different products to clients across pharmaceutical, food, and nutrition sectors. Sudeep Pharma maintains strong research and development capabilities, supported by in-house laboratories and pilot-scale facilities focused on mineral salts and excipients.
Ownership Structure and Financial Performance
The Bhayani family, serving as promoters, currently holds an 89.37% stake in the company. Public shareholders own the remaining 10.63%, with Nuvama Crossover Opportunities Fund maintaining a significant 8.24% stake among public holdings.
Financially, Sudeep Pharma has demonstrated robust performance. For the quarter ending June 2025, the company reported a profit of ₹31.3 crore on revenues of ₹124.9 crore. The fiscal year ending March 2025 showed even stronger results, with profits reaching ₹138.7 crore, representing a 4.1% increase from the previous year's ₹133.2 crore. Revenue growth was equally impressive, climbing 9.3% to ₹502 crore from ₹459.3 crore in the prior fiscal year.
The IPO is being managed by reputable merchant bankers ICICI Securities and IIFL Capital Services, adding credibility to the offering and ensuring professional execution of the public issue process.
